Chinese herbal formulas alleviated depression in breast cancer patients: A meta-analysis, network pharmacology and experimental validation

Read full text Summarise with VIRAT
Authors: Shicui Hong, Yu-Yi Du, Gui-Bin Wang, Shengqi Wang, Yi-Feng Zheng, Neng Wang, Honglin Situ, Zhi-Yu Wang
Cited by: 0
References: 70

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND Depression represents a frequent comorbidity in breast cancer patients. However, many antidepressants have a certain degree of adverse reactions and decline patients’ compliance to conventional therapies. Chinese herbal formulas (CHF), with its long-standing application in mood disorders, offers a potential alternative. Nevertheless, comprehensive evidence regarding its effectiveness specifically for depression in breast cancer populations remains limited. AIM To systematically evaluate the efficacy of CHF interventions for depression in breast cancer patients and explore the potential mechanisms. METHODS We systematically searched four English databases (PubMed, EMBASE, the Cochrane Library, PsycINFO) and four Chinese databases (CNKI, CBM, VIP, Wanfang) from their inception through June 2024. The investigation focused on CHF’s effects on psychological outcomes [depression and quality of life (QOL)], neurochemical parameters (serotonin, norepinephrine, and dopamine levels) and immunological indicators (CD4+ and CD8+ T lymphocyte counts). Network pharmacology and experimental analysis of clinical samples were employed to elucidate the mechanisms of the core formula Si-Ni-San (SNS). RESULTS Pooled data from 20 randomized trials (n = 1607) demonstrated CHF’s superiority over antidepressants in reducing Hamilton Depression Rating Scale scores (mean difference = -5.33, 95% confidence interval: -6.93 to -3.73, P < 0.05) and enhancing QOL (mean difference = 9.13, 95% confidence interval: 6.69-11.57, P < 0.05). CHF significantly elevated monoamine neurotransmitter levels (all P < 0.05) and CD4+ T cell counts (P < 0.05), with no effect on CD8+ subsets. Subgroup analysis revealed enhanced efficacy with interventions ≥ 4 weeks. Safety profiles favored CHF, with fewer adverse events vs antidepressants. Network pharmacology analysis suggested that SNS may exert its effects by modulating immune responses and serotonergic synapse pathways. Experimental analysis of clinical samples further indicated that the antidepressant effects of SNS may be mediated through the regulation of CD4+ T cells and rebalancing of neurotransmitter, tryptophan metabolism. CONCLUSION This systematic review establishes CHF as an effective and safe intervention for depression in breast cancer patients, with benefits extending to QOL, monoamine neurotransmitter levels and immunological parameters. Moreover, SNS represents a promising complementary therapy with multi-pathway mechanisms of action, particularly involving immune and metabolic pathways.

Fields of Study & Subjects

Medicinal Plant Extracts Effects Traditional Chinese Medicine Clinical Research Cancer survivorship and care

Publication details

Journal / source
World Journal of Psychiatry
Volume
16
Issue
4
Publication date
27 March 2026
Language
EN